Zacks Investment Research on MSN
Vertex stock down nearly 8% in 3 months: Time to buy or stay cautious?
Vertex Pharmaceuticals Incorporated VRTX stock has declined 7.9% in the past three months. One major reason for the weakness ...
Vertex Pharmaceuticals VRTX reported strong second-quarter results driven by the continued robust uptake of its cystic fibrosis triple-combination therapy, Trikafta/Kaftrio. Product revenue of $2.49 ...
Vertex VRTX reported third-quarter results highlighted by strong uptake of its cystic fibrosis triple combination therapy, Trikafta/Kaftrio, in the United States and internationally. Quarterly product ...
Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts ...
24/7 Wall St. on MSN
Got $5,000? 1 cash-flow king to buy and hold forever that Wall Street is completely mispricing
Quick Read Vertex generated $3.19 billion free cash flow in 2025 while repurchasing $2.02 billion in shares, funding both ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor ...
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have at ...
(RTTNews) - Vertex Pharmaceuticals (VRTX) said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of ...
Cystic fibrosis (CF) patients and their families in England can rest a little easier this week, thanks to an extended long-term reimbursement deal inked by Vertex Pharmaceuticals and the country’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results